Table 2.
Univariate and multivariate analysis of predictors of immunologic failure
| Characteristics | Unadjusted RR PR (95% CI) |
p-value1 | Adjusted PRR (95% CI) |
p-value2 |
|---|---|---|---|---|
| Gender | ||||
| Male | 1.00 | 1.00 | ||
| Female | 0.98 (0.88–1.09) | 0.17 | 1.22 (1.07–1.40) | 0.005 |
| Occupation | ||||
| Employed | 0.92 (0.80–1.05) | 0.19 | 1.18 (0.95–1.46) | 0.14 |
| Others | 1.00 | 1.00 | ||
| Service entry point | ||||
| Voluntary counseling and testing | 0.78 (0.70–0.88) | < 0.001 | 0.79 (0.64–0.91) | 0.002 |
| Others | 1.00 | 1.00 | ||
| NVP containing regimen | ||||
| Yes | 1.35 (1.18–1.54) | < 0.001 | 1.21 (0.99–1.45) | 0.23 |
| No | 1.00 | 1.00 | ||
| WHO stage | ||||
| 1 or 2 | 1.00 | 0.14 | 1.00 | 0.013 |
| 3 or 4 | 0.97 (0.84–1.19) | 0.76 (0.60–0.96) | ||
| CD4 cell count, cells/mm3 | ||||
| 200 + | 0.22 (0.20–0.24) | 0.19 (0.16–0.22) | ||
| < 200 | 1.00 | < 0.001 | 1.00 | < 0.001 |
1Prevalence RatioRelative risk (PRRR), 95% confidence interval (CI) and p-values were calculated using log binomial regression
2Multivariate models included all predictors significant at p value < 0.20